These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25068419)

  • 1. The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma.
    Jaglowski SM; Ruppert AS; Hofmeister CC; Elder P; Blum W; Klisovic R; Vasu S; Penza S; Efebera YA; Benson DM; Devine SM; Andritsos LA
    Bone Marrow Transplant; 2014 Oct; 49(10):1323-9. PubMed ID: 25068419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation.
    El-Jawahri A; Chen YB; Brazauskas R; He N; Lee SJ; Knight JM; Majhail N; Buchbinder D; Schears RM; Wirk BM; Wood WA; Ahmed I; Aljurf M; Szer J; Beattie SM; Battiwalla M; Dandoy C; Diaz MA; D'Souza A; Freytes CO; Gajewski J; Gergis U; Hashmi SK; Jakubowski A; Kamble RT; Kindwall-Keller T; Lazarus HM; Malone AK; Marks DI; Meehan K; Savani BN; Olsson RF; Rizzieri D; Steinberg A; Speckhart D; Szwajcer D; Schoemans H; Seo S; Ustun C; Atsuta Y; Dalal J; Sales-Bonfim C; Khera N; Hahn T; Saber W
    Cancer; 2017 May; 123(10):1828-1838. PubMed ID: 28102896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of comorbidity on survival and collected CD34 + cell counts in autologous hematopoietic stem cell transplant patients.
    Sarıcı A; Erkurt MA; Kuku İ; Bahçecioğlu ÖF; Biçim S; Kaya E; Berber İ; Keser MF; Gök S; Özgül M
    Transfus Apher Sci; 2022 Feb; 61(1):103296. PubMed ID: 34696982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Morbidity and Mortality in Autologous Stem Cell Transplantation.
    Berro M; Arbelbide JA; Rivas MM; Basquiera AL; Ferini G; Vitriu A; Foncuberta C; Fernandez Escobar N; Requejo A; Milovic V; Yantorno S; Szelagoswki M; Martinez Rolon J; Bentolila G; Garcia JJ; Garcia P; Caeiro G; Castro M; Jaimovich G; Palmer S; Trucco JI; Bet LA; Shaw BE; Kusminsky GD
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1646-1650. PubMed ID: 28669923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.
    Saad A; Mahindra A; Zhang MJ; Zhong X; Costa LJ; Dispenzieri A; Drobyski WR; Freytes CO; Gale RP; Gasparetto CJ; Holmberg LA; Kamble RT; Krishnan AY; Kyle RA; Marks D; Nishihori T; Pasquini MC; Ramanathan M; Lonial S; Savani BN; Saber W; Sharma M; Sorror ML; Wirk BM; Hari PN
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):402-408.e1. PubMed ID: 24342394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality patterns among recipients of autologous hematopoietic stem cell transplantation for lymphoma and myeloma in the past three decades.
    Bhatt VR; Loberiza FR; Jing H; Bociek RG; Bierman PJ; Maness LJ; Vose JM; Armitage JO; Akhtari M
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):409-415.e1. PubMed ID: 25816932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.
    Farina L; Bruno B; Patriarca F; Spina F; Sorasio R; Morelli M; Fanin R; Boccadoro M; Corradini P
    Leukemia; 2009 Jun; 23(6):1131-8. PubMed ID: 19194465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis.
    Sun L; Li S; El-Jawahri A; Armand P; Dey BR; Fisher DC; Jacobsen ED; Jacobson CA; LaCasce AS; McAfee SL; Spitzer TR; Chen YB; DeFilipp Z
    Oncologist; 2018 May; 23(5):624-630. PubMed ID: 29284757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation.
    Pollack SM; Steinberg SM; Odom J; Dean RM; Fowler DH; Bishop MR
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):223-30. PubMed ID: 19167682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors of early disease progression and decreased survival for multiple myeloma patients after upfront autologous stem cell transplantation.
    Hsu TL; Tsai CK; Liu CY; Yeh CM; Lin FL; Hsiao LT; Liu YC; Chien SH; Wang HY; Ko PS; Lin TA; Chen WC; Chen PM; Liu JH; Gau JP; Liu CJ
    Ann Hematol; 2024 Aug; 103(8):2893-2904. PubMed ID: 38472362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
    Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
    Cowan AJ; Stevenson PA; Libby EN; Becker PS; Coffey DG; Green DJ; Hyun TS; Fromm JR; Gopal AK; Holmberg LA
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1386-1391. PubMed ID: 29481870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation.
    Chakraborty R; Muchtar E; Kumar SK; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
    Bone Marrow Transplant; 2018 Feb; 53(2):155-161. PubMed ID: 29131152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormal body composition is a predictor of adverse outcomes after autologous haematopoietic cell transplantation.
    Armenian SH; Iukuridze A; Teh JB; Mascarenhas K; Herrera A; McCune JS; Zain JM; Mostoufi-Moab S; McCormack S; Slavin TP; Scott JM; Jones LW; Sun CL; Forman SJ; Wong FL; Nakamura R
    J Cachexia Sarcopenia Muscle; 2020 Aug; 11(4):962-972. PubMed ID: 32212263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens.
    Maymani H; Lin P; Saliba RM; Popat U; Bashir Q; Shah N; Patel K; Parmar S; Kebriaei P; Hosing C; Ciurea S; Andersson B; Shpall E; Champlin R; Srour SA; Qazilbash MH
    Biol Blood Marrow Transplant; 2019 May; 25(5):1039-1044. PubMed ID: 30639822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study.
    Lawless S; Sbianchi G; Morris C; Iacobelli S; Bosman P; Blaise D; Reményi P; Byrne JL; Mayer J; Apperley J; Lund J; Kobbe G; Schaap N; Isaksson C; Lenhoff S; Basak G; Touzeau C; Wilson KMO; González Muñiz S; Scheid C; Browne P; Anagnostopoulos A; Rambaldi A; Jantunen E; Kröger N; Schönland S; Yakoub-Agha I; Garderet L
    Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):686-693. PubMed ID: 34158265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Performance Status and Hematopoietic Cell Transplantation Specific Comorbidity Index on Unplanned Admission Rates in Patients with Multiple Myeloma Undergoing Outpatient Autologous Stem Cell Transplantation.
    Obiozor C; Subramaniam DP; Divine C; Shune L; Singh AK; Lin TL; Abhyankar S; Chen GJ; McGuirk J; Ganguly S
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1641-1645. PubMed ID: 28603071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma.
    Maloney DG; Molina AJ; Sahebi F; Stockerl-Goldstein KE; Sandmaier BM; Bensinger W; Storer B; Hegenbart U; Somlo G; Chauncey T; Bruno B; Appelbaum FR; Blume KG; Forman SJ; McSweeney P; Storb R
    Blood; 2003 Nov; 102(9):3447-54. PubMed ID: 12855572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
    Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
    Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.